Peptech Announces Director Retirements
Peptech Limited (ASX:PTD, AIM: PTDx) today announced as part of its merger agreement with EvoGenix that Martin Kriewaldt
and Till Medinger will retire as directors of the company, effective 28 August 2007.
Mel Bridges, Chairman of Peptech thanked both directors for the services provided to the company, commenting:
"Till has been a director of the company since 1997. He has been a consistent contributor at board level, with his
international industry knowledge being particularly valuable. As Peptech's alternate director on the Domantis board,
Till was instrumental in Peptech's continuing participation in Domantis and the very successful realisation of that
investment.
"Since joining the Peptech Board in October 2003, Martin's litigation experience has been particularly invaluable in the
disputes Peptech had with Centocor and Abbott. More recently he has used his skills in guiding Peptech through its
merger and acquisition activity, spending considerable time on due diligence activities. "On behalf of the entire
Peptech board I sincerely thank both these directors for their commitment to Peptech," he added.
Effective from 28 August 2007, Chris Harris and Robin Beaumont, formerly directors of EvoGenix Limited, will join the
Peptech Board.
About Peptech:
Peptech Limited is a biotechnology company dedicated to developing and providing antibody and peptide-based human
therapeutic products for the treatment of cancer and inflammatory diseases.
The Company has tapped its unique antibody technologies and revenues generated from its pioneering anti-TNF patents to
build a range of therapeutic assets to address large and clinically validated markets.
Peptech is transitioning to a mid-stage development company as several products move from pre-clinical stages into human
trials, starting with the Company's lead compound, PN0621, a differentiated anti-TNF domain antibody construct.
ENDS